Return to homepagePandemic Pact

THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A

  • Funded by Biomedical Advanced Research and Development Authority (BARDA)
  • Total publications:0 publications

Grant number: 75A50122C00079

Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    2023
    2027

  • Known Financial Commitments (USD)

    $15,504,106

  • Funder

    Biomedical Advanced Research and Development Authority (BARDA)

  • Research Location

    United States of America

  • Lead Research Institution

    ORASURE TECHNOLOGIES INC

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A SECOND-GENERATION ASSAY FOR THE ORAQUICK EBOLA RAPID ANTIGEN TEST AS A SUSTAINABLE, ENHANCED TEST INCLUDING ALTERNATIVE REAGENTS (ANTIBODY AND ANTIGEN) WITH CONTINUED AVAILABILITY, EXTENDED SHELF-LIFE, A